Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

Authors

JC Park
Rachel Sanborn, ProvidenceFollow
See full list of authors in comments

Document Type

Abstract

Publication Date

11-1-2023

Keywords

oregon; chiles

Clinical Institute

Cancer

Department

Oncology

Comments

Park JC, Berz D, Sharma M, Massarelli E, Hauke RJ, Tsai FY-C, Hong D, Akhave N, Call JA, Carlisle J, Sanborn RE, Haas NB, Hamm J, Camidge DR, Spira AI, Andrianov V, O’Neill B, Kinkead H, Tolcher AW. SITC Annual Meeting; November 1-5; San Diego, CA. 2023;11(Suppl 1): 742.

Recommended Citation

Park, JC; Sanborn, Rachel; and See full list of authors in comments, "Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors" (2023). Articles, Abstracts, and Reports. 8364.
https://digitalcommons.providence.org/publications/8364